To date, there is limited data on levels of platelet inhibition achieved in patients with
ST-elevation myocardial infarction (
STEMI) who are loaded with
clopidogrel and
aspirin (ASA) prior to undergoing primary
percutaneous coronary intervention (P-PCI). The aim of this investigation was to evaluate the percentage of
STEMI patients with high on-treatment platelet reactivity (HPR) to
clopidogrel at the time of initiating P-PCI and its association with the initial patency of the
infarct-related artery (IRA). This prospective pharmacodynamic study included 50
STEMI patients, previously naïve to oral
antiplatelet agents, who received 500-mg ASA and 600-mg
clopidogrel loading doses prior to P-PCI. Platelet function assessment was performed at the beginning of the procedure using various assays, including VerifyNow™ system (primary endpoint), light transmission aggregometry and multiple
electrode aggregometry. The percentage of patients with suboptimal response to
clopidogrel and ASA assessed with the VerifyNow™ system was 88.0% and 28.6%, respectively. Similar results were obtained with the other assays used. A higher percentage of patients with initial patency of the IRA was observed among those patients without HPR compared with those with HPR to
clopidogrel (66.7% vs 15.9%; p=0.013), while no differences were observed regarding postprocedural angiographic or electrocardiographic outcomes. In conclusion, this study shows that a high percentage of
STEMI patients have inadequate levels of
clopidogrel-induced and, to a lesser extent,
aspirin-mediated platelet inhibition when starting a P-PCI procedure, and suggests that a poor response to
clopidogrel might be associated with impaired initial TIMI flow in the IRA.